46 research outputs found
N-3 PUFAs induce inflammatory tolerance by formation of KEAP1-containing SQSTM1/p62-bodies and activation of NFE2L2
Inflammation is crucial in the defense against infections but must be tightly controlled to limit detrimental hyperactivation. Our diet influences inflammatory processes and omega-3 polyunsaturated fatty acids (n-3 PUFAs) have known anti-inflammatory effects. The balance of pro- and anti-inflammatory processes is coordinated by macrophages and macroautophagy/autophagy has recently emerged as a cellular process that dampens inflammation. Here we report that the n-3 PUFA docosahexaenoic acid (DHA) transiently induces cytosolic speckles of the autophagic receptor SQSTM1/p62 (sequestosome 1) (described as SQSTM1/p62-bodies) in macrophages. We suggest that the formation of SQSTM1/p62-bodies represents a fast mechanism of NFE2L2/Nrf2 (nuclear factor, erythroid 2 like 2) activation by recruitment of KEAP1 (kelch like ECH associated protein 1). Further, the autophagy receptor TAX1BP1 (Tax1 binding protein 1) and ubiquitin-editing enzyme TNFAIP3/A20 (TNF α induced protein 3) could be identified in DHA-induced SQSTM1/p62-bodies. Simultaneously, DHA strongly dampened the induction of pro-inflammatory genes including CXCL10 (C-X-C motif chemokine ligand 10) and we suggest that formation of SQSTM1/p62-bodies and activation of NFE2L2 leads to tolerance towards selective inflammatory stimuli. Finally, reduced CXCL10 levels were related to the improved clinical outcome in n-3 PUFA-supplemented heart-transplant patients and we propose CXCL10 as a robust marker for the clinical benefits mobilized by n-3 PUFA supplementation
Receptors involved in cell activation by defined uronic acid polymers and bacterial components
<b>PAPER 1</b> In the first paper we show that reducing the average molecular weight from ~350 kDa to <6kDa by acid hydrolysis diminished the cell-stimulating activity of poly-M, measured as TNFproduction from human monocytes. However, the activity of the resulting oligomers (M-blocks) was greatly enhanced when covalently attached to particles (plastic beads or biodegradable albumin particles). Similar results were obtained with detoxified/deacylated LPS (DLPS) and glucuronic acid polymers (C6OXY), but not with G-blocks that by themselves are not active. These results suggest that the supramolecular structure affects the potency of polysaccharide stimuli, and that M-blocks attached to biodegradable albumin particles could possibly be exploited as an immunostimulant for protection against various diseases. <b>PAPER 2</b> In paper 2, according to the reviewers suggestion, the designation M-polymers of different molecular size was used in place of poly-M (~350 kDa) and M-blocks (~3 kDa). In this study we demonstrated that M-blocks and DLPS attached to particles engaged different receptors than soluble poly-M and DLPS in activation of monocytes. By using blocking mAbs to CD14, CD11b and CD18, we found that particulate stimuli employed the β2- integrin CD11b/CD18 in addition to the shared CD14 for signaling TNF-production. Moreover, whereas poly-M only bound to CD14-expressing CHO-cells, M-particles preferentially bound to CHO-cells expressing β2-integrins. However, the DLPS- and M-particles failed to activate NF-κB-translocation in CHO-cells co-transfected with CD14 and β2-integrins, suggesting that additional molecules are required for activation of CHO-cells. The major conclusion drawn from this work is that the supramolecular structure, in addition to influence the potency, affects the cellular receptor engagement by carbohydrates like poly-M and DLPS. This points to the importance of comparing the mechanisms involved in activation of immune cells by soluble bacterial components and whole bacteria to achieve a better understanding of inflammatory diseases like sepsis. <b>PAPER 3</b> Poly-M activates cells in a CD14-dependent manner, but CD14 is linked to the membrane with a GPI-anchor and mediates activation by interaction with other, signal-transducing molecules, like the TLRs. By using blocking mAbs to TLR2 (generated in our lab, paper 5) and TLR4, we found that both receptors were involved in mediating TNF-production from human monocytes in response to poly-M. Furthermore, TLR4 mutant (C3H/HeJ) and knockout (TLR4-/-) murine macrophages were completely non-responsive to poly-M, whereas TLR2-deficient macrophages showed reduced TNF-responses. These findings indicate that CD14, TLR2 and TLR4 on primary cells all participate in cytokine-induction by poly-M, and that TLR4 may be necessary for activation. <b>PAPER 4</b> In addition to CD14, β2-integrins have been implicated in LPS-induced cellular activation, and in this study we compared the involvement of CD14 and β2-integrins in TNF-production and NF-κB-activation induced by LPS and GBS cell wall fragments. With blocking mAbs to CD14 and CD18 we found that LPS and GBS cell walls shared CD14, but in addition the cell walls employed CD11/CD18 in mediating TNF-production from human monocytes. Both stimuli specifically induced NF-κB-translocation in CD14-transfected CHO-cells, but only LPS could activate cells transfected with CD11/CD18. The lack of response to GBS cell walls in CD11/CD18-transfected CHO-cells indicated that the cell walls need CD14 for cell activation. Further in paper 4 we demonstrate the ability of GBS cell walls to activate LPS-hyporesponsiv C3H/HeJ mouse macrophages, suggesting that LPS and GBS cell walls employ different receptors/signaling mechanisms in murine macrophages. <b>PAPER 5</b> When it was discovered that human TLR2 and TLR4 are involved in microbial recognition, we started to generate a mouse mAb to human TLR2, and in paper 5 we report the production and characterization of the mAb TL2.1. We subsequently used this mAb to evaluate the role of TLR2 in mediating activation by heat-killed GBS and L monocytogenes. L. monocytogenes, but not GBS, activated TLR2-transfected CHO-cells to IL-6-production, and the response was inhibited by TL2.1. A CD14 mAb and TL2.1 both inhibited TNF-production from monocytes induced by L. monocytogenes, but neither mAb affected the TNF-response triggered by GBS. Our results suggest that CD14 and TLR2 are engaged in cell activation by L. monocytogenes, but that neither receptor seem to be involved in activation by GBS. This study was the first to show that human TLR2 can discriminate between two G+ bacteria. <b>PAPER 6</b> In paper 6 we report the generation of a new TLR2 mAb, TL2.3, that stained with the same specificity as TL2.1 (anti-TLR2, paper 5). We used these mAbs to investigate the expression of TLR2 protein in human cells. We found that TLR2 was highly expressed in blood monocytes, less in granulocytes, and not present in lymphocytes. The protein level was measured on quiescent and activated cells by extra- and intracellular flow cytometry, and by immunoprecipitation of TLR2 from metabolic S35-labeled cells. Surprisingly, TLR2 protein was detected in activated B-cells located in lymphoid germinal centers, indicating that subsets of lymphocytes may express TLR2. We further show that TLR2 protein was differentially regulated on monocytes and granulocytes after exposure to LPS, pro- or anti-inflammatory cytokines. However, we could not correlate the regulation of TLR2 to cellular responses, as for instance the three anti-inflammatory cytokines TGFβ, IL-4 and IL-10 all inhibited lipopeptideinduced TNF-production, but either did not affect, reduced, or increased the level of surface TLR2, respectively. Thus, the biological significance of TLR2-regulation remains to be found
Persistent Mycobacteria Evade an Antibacterial Program Mediated by Phagolysosomal TLR7/8/MyD88 in Human Primary Macrophages, 2019
FRIMEDBIO project 2013-2018. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and is a global health problem. At the same time, epidemiological data show that the incidence of non-tuberculous mycobacterial infection with opportunistic M. avium is increasing, especially in countries where tuberculosis is not endemic and in people with impaired immune systems. The treatment of mycobacterial infections is complicated and long-lasting and there is increasing incidence of resistance. Therefore, there is a great need for new and more effective treatment. In this project, the main goal has been to understand the molecular mechanisms that the macrophage uses in an attempt to eliminate mycobacteria and, conversely, how the mycobacteria bypass these and take up residence in the macrophage. Knowledge from research on innate immune responses to mycobacteria was used to study similar responses in T cells and the importance of HIV infection
Sensing of HIV-1 by TLR8 Activates Human T Cells and Reverses, 2019
FRIMEDBIO project 2013-2018. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and is a global health problem. At the same time, epidemiological data show that the incidence of non-tuberculous mycobacterial infection with opportunistic M. avium is increasing, especially in countries where tuberculosis is not endemic and in people with impaired immune systems. The treatment of mycobacterial infections is complicated and long-lasting and there is increasing incidence of resistance. Therefore, there is a great need for new and more effective treatment. In this project, the main objective has been to understand the molecular mechanisms that the macrophage uses in an attempt to eliminate mycobacteria and, conversely, how the mycobacteria bypass these and take up residence in the macrophage. We have also used the knowledge we have from research on innate immune responses to mycobacteria to study similar responses in T cells and the importance of HIV infection
Keap1 regulates inflammatory signaling in Mycobacterium avium-infected human macrophages, 2019
FRIMEDBIO project 2013-2018. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and is a global health problem. At the same time, epidemiological data show that the incidence of non-tuberculous mycobacterial infection with opportunistic M. avium is increasing, especially in countries where tuberculosis is not endemic and in people with impaired immune systems. The treatment of mycobacterial infections is complicated and long-lasting and there is increasing incidence of resistance. Therefore, there is a great need for new and more effective treatment. In this project, the main objective has been to understand the molecular mechanisms that the macrophage uses in an attempt to eliminate mycobacteria and, conversely, how the mycobacteria bypass these and take up residence in the macrophage. Knowledge from research on innate immune responses to mycobacteria was used to study similar responses in T cells and the importance of HIV infection
Molecular basis of mycobacterial survival in macrophages
Macrophages play an essential role in the immune system by ingesting and degrading invading pathogens, initiating an inflammatory response and instructing adaptive immune cells, and resolving inflammation to restore homeostasis. More interesting is the fact that some bacteria have evolved to use macrophages as a natural habitat and tools of spread in the host, e.g., Mycobacterium tuberculosis (Mtb) and some non-tuberculous mycobacteria (NTM). Mtb is considered one of humanity’s most successful pathogens and is the causal agent of tuberculosis, while NTMs cause opportunistic infections all of which are of significant public health concern. Here, we describe mechanisms by which intracellular pathogens, with an emphasis on mycobacteria, manipulate macrophage functions to circumvent killing and live inside these cells even under considerable immunological pressure. Such macrophage functions include the selective evasion or engagement of pattern recognition receptors, production of cytokines, reactive oxygen and nitrogen species, phagosome maturation, as well as other killing mechanisms like autophagy and cell death. A clear understanding of host responses elicited by a specific pathogen and strategies employed by the microbe to evade or exploit these is of significant importance for the development of effective vaccines and targeted immunotherapy against persistent intracellular infections like tuberculosis
Mycobacterium smegmatis Vaccine Vector Elicits CD4+ Th17 and CD8+ Tc17 T Cells With Therapeutic Potential to Infections With Mycobacterium avium
Mycobacterium avium (Mav) complex is increasingly reported to cause non-tuberculous infections in individuals with a compromised immune system. Treatment is complicated and no vaccines are available. Previous studies have shown some potential of using genetically modified Mycobacterium smegmatis (Msm) as a vaccine vector to tuberculosis since it is non-pathogenic and thus would be tolerated by immunocompromised individuals. In this study, we used a mutant strain of Msm disrupted in EspG3, a component of the ESX-3 secretion system. Infection of macrophages and dendritic cells with Msm ΔespG3 showed increased antigen presentation compared to cells infected with wild-type Msm. Vaccination of mice with Msm ΔespG3, expressing the Mav antigen MPT64, provided equal protection against Mav infection as the tuberculosis vaccine, Mycobacterium bovis BCG. However, upon challenge with Mav, we observed a high frequency of IL-17-producing CD4+ (Th17 cells) and CD8+ (Tc17 cells) T cells in mice vaccinated with Msm ΔespG3::mpt64 that was not seen in BCG-vaccinated mice. Adoptive transfer of cells from Msm ΔespG3-vaccinated mice showed that cells from the T cell compartment contributed to protection from Mav infection. Further experiments revealed Tc17-enriched T cells did not provide prophylactic protection against subsequent Mav infection, but a therapeutic effect was observed when Tc17-enriched cells were transferred to mice already infected with Mav. These initial findings are important, as they suggest a previously unknown role of Tc17 cells in mycobacterial infections. Taken together, Msm ΔespG3 shows promise as a vaccine vector against Mav and possibly other (myco)bacterial infections
The Tumor Necrosis Factor Alpha and Interleukin 6 Auto-paracrine Signaling Loop Controls Mycobacterium avium Infection via Induction of IRF1/IRG1 in Human Primary Macrophages
Macrophages sense and respond to pathogens by induction of antimicrobial and inflammatory programs to alert other immune cells and eliminate the infectious threat. We have previously identified the transcription factor IRF1 to be consistently activated in macrophages during Mycobacterium avium infection, but its precise role during infection is not clear. Here, we show that tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) autocrine/paracrine signaling contributes to controlling the intracellular growth of M. avium in human primary macrophages through activation of IRF1 nuclear translocation and expression of IRG1, a mitochondrial enzyme that produces the antimicrobial metabolite itaconate. Small interfering RNA (siRNA)-mediated knockdown of IRF1 or IRG1 increased the mycobacterial load, whereas exogenously provided itaconate was bacteriostatic at high concentrations. While the overall level of endogenous itaconate was low in M. avium-infected macrophages, the repositioning of mitochondria to M. avium phagosomes suggests a mechanism by which itaconate can be delivered directly to M. avium phagosomes in sufficient quantities to inhibit growth. Using mRNA hybridization, we further show that uninfected bystander cells actively contribute to the resolution of infection by producing IL-6 and TNF-α, which, via paracrine signaling, activate IRF1/IRG1 and strengthen the antimicrobial activity of infected macrophages. This mechanism contributes to the understanding of why patients on anti-inflammatory treatment, e.g., with tocilizumab or infliximab, can be more susceptible to mycobacterial disease
Persistent mycobacteria evade an antibacterial program mediated by phagolysosomal TLR7/8/MyD88 in human primary macrophages.
Pathogenic mycobacteria reside in macrophages where they avoid lysosomal targeting and degradation through poorly understood mechanisms proposed to involve arrest of phagosomal maturation at an early endosomal stage. A clear understanding of how this relates to host defenses elicited from various intracellular compartments is also missing and can only be studied using techniques allowing single cell and subcellular analyses. Using confocal imaging of human primary macrophages infected with Mycobacterium avium (Mav) we show evidence that Mav phagosomes are not arrested at an early endosomal stage, but mature to a (LAMP1+/LAMP2+/CD63+) late endosomal/phagolysosomal stage where inflammatory signaling and Mav growth restriction is initiated through a mechanism involving Toll-like receptors (TLR) 7 and 8, the adaptor MyD88 and transcription factors NF-κB and IRF-1. Furthermore, a fraction of the mycobacteria re-establish in a less hostile compartment (LAMP1-/LAMP2-/CD63-) where they not only evade destruction, but also recognition by TLRs, growth restriction and inflammatory host responses that could be detrimental for intracellular survival and establishment of chronic infections